Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06649201 · ClinicalTrials.gov registry record
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
A clinical trial of Graft Vs Host Disease and Vulvovaginal Signs and Symptoms, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT06649201: Recruiting study of Graft Vs Host Disease and Vulvovaginal Signs and Symptoms, sponsored by Case Comprehensive Cancer Center.
NCT06649201 is a study of Graft Vs Host Disease and Vulvovaginal Signs and Symptoms that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 40 participants, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06649201, a study of Graft Vs Host Disease and Vulvovaginal Signs and Symptoms, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to investigate the development of vulvovaginal graft-versus-host- disease (GVHD), an under-reported and under-recognized manifestation of chronic GVHD. This study aims to characterize the vaginal microbiome in participants undergoing allogeneic hematopoietic cell transplantation (HCT). The main questions it aims to answer are: * Is the vaginal microbiome altered during allogeneic HCT? * What changes may help researchers understand the development of vulvovaginal GVHD? Participants will be asked to undergo an assessment of vulvovaginal symptoms through a vulvovaginal symptom questionnaire once pre-transplant, 6 months post-transplant, and twelve12 months post- transplant. Participants will also be asked to undergo a vaginal microbiome (collection of bacteria, fungi, and viruses that live on our bodies) evaluation through a vaginal exam performed by a gynecologist with collection of vaginal samples once pre-transplant and again six months post-treatment and twelve months post-transplant. If a participant develops symptoms of vulvovaginal GVHD at any point in time during the post-transplant follow up, the participant may partake in additional vaginal exams to diagnose GVHD at the time of symptom onset.
Primary Outcome
A primary objective of this study is to characterize the vaginal microbiome and in female participants undergoing allogeneic HCT.
Conditions Studied
Interventions
- OTHER Vulvovaginal Symptom Questionnaire
- DIAGNOSTIC_TEST Vaginal Microbiome Evaluation
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2027-02-15 |
What NCT06649201 shows while recruiting
NCT06649201 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Graft Vs Host Disease appearing as the primary indexed condition, and to 2 interventions - of which Vulvovaginal Symptom Questionnaire is the first listed.
NCT06649201 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06649201 about?
NCT06649201 is a clinical study titled "Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation". The goal of this observational study is to investigate the development of vulvovaginal graft-versus-host- disease (GVHD), an under-reported and under-recognized manifestation of chronic GVHD. This study aims to characterize the vaginal microbiome in participants undergoing allogeneic hematopoietic c...
What is the current status of trial NCT06649201?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2024-12-19. Estimated completion is 2027-02-15.
What conditions does trial NCT06649201 study?
This clinical trial studies the following conditions: Graft Vs Host Disease, Vulvovaginal Signs and Symptoms.
What interventions are being tested in trial NCT06649201?
The interventions under investigation include: Vulvovaginal Symptom Questionnaire (OTHER), Vaginal Microbiome Evaluation (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06649201?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06649201 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06649201's enrollment target sits among peer trials
40 21st of 36 higher than 14 of 36 other Graft Vs Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graft Vs Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
RECRUITING · NA
-
IS-free Treg HaploHCT
RECRUITING · Phase 1
-
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 2
-
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
RECRUITING · Phase 1
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
-
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI